Cefminox

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Cefminox
DrugBank Accession Number
DB09062
Background

Cefminox (INN) is a second generation cephalosporin antibiotic. It is approved for use in Japan.

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 519.57
Monoisotopic: 519.066459566
Chemical Formula
C16H21N7O7S3
Synonyms
  • Cefminox
  • cefminoxum
  • CMNX

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Treatment ofSusceptible bacterial infections•••••••••••••••••••••• ••••••• ••• ••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirCefminox may decrease the excretion rate of Abacavir which could result in a higher serum level.
AbciximabThe therapeutic efficacy of Abciximab can be decreased when used in combination with Cefminox.
AceclofenacThe risk or severity of nephrotoxicity can be increased when Aceclofenac is combined with Cefminox.
AcemetacinThe risk or severity of nephrotoxicity can be increased when Cefminox is combined with Acemetacin.
AcenocoumarolThe risk or severity of bleeding can be increased when Cefminox is combined with Acenocoumarol.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Cefminox sodiumYNM4DBJ3N875498-96-3SBIDXLKJYJVQOE-YNJMIPHHSA-M
Cefminox sodium hydrateKZ89N378LQ1351813-81-4QCIJKKRQPRMHOX-IJARWDBPSA-M
International/Other Brands
Meicelin

Categories

ATC Codes
J01DC12 — Cefminox
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as cephamycins. These are compounds containing a the cephalosporin (oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid) nucleus, with an alkyloxy group attached to the C6 carbon atom.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Lactams
Sub Class
Beta lactams
Direct Parent
Cephamycins
Alternative Parents
N-acyl-alpha amino acids and derivatives / Cysteine and derivatives / S-alkyl-L-cysteines / D-alpha-amino acids / Alkylarylthioethers / Dicarboxylic acids and derivatives / 1,3-thiazines / Tetrazoles / Tertiary carboxylic acid amides / Heteroaromatic compounds
show 13 more
Substituents
Alkylarylthioether / Alpha-amino acid / Alpha-amino acid or derivatives / Amine / Amino acid / Amino acid or derivatives / Aromatic heteropolycyclic compound / Aryl thioether / Azacycle / Azetidine
show 30 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
PW08Y13465
CAS number
84305-41-9
InChI Key
JSDXOWVAHXDYCU-VXSYNFHWSA-N
InChI
InChI=1S/C16H21N7O7S3/c1-22-15(19-20-21-22)33-4-7-3-32-14-16(30-2,13(29)23(14)10(7)12(27)28)18-9(24)6-31-5-8(17)11(25)26/h8,14H,3-6,17H2,1-2H3,(H,18,24)(H,25,26)(H,27,28)/t8-,14-,16+/m1/s1
IUPAC Name
(6R,7S)-7-(2-{[(2S)-2-amino-2-carboxyethyl]sulfanyl}acetamido)-7-methoxy-3-{[(1-methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
SMILES
[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)CSC[C@@H](N)C(O)=O)OC)C(O)=O

References

General References
Not Available
KEGG Drug
D07642
ChemSpider
64286
ChEBI
135817
ChEMBL
CHEMBL1276342
ZINC
ZINC000003938624
Drugs.com
Drugs.com Drug Page
Wikipedia
Cefminox

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.09 mg/mLALOGPS
logP-1.5ALOGPS
logP-3.6Chemaxon
logS-2.7ALOGPS
pKa (Strongest Acidic)1.56Chemaxon
pKa (Strongest Basic)8.82Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count11Chemaxon
Hydrogen Donor Count4Chemaxon
Polar Surface Area202.86 Å2Chemaxon
Rotatable Bond Count11Chemaxon
Refractivity133.34 m3·mol-1Chemaxon
Polarizability48.92 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0fk9-0103980000-b7423378dc384967d6d1
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-066r-2609010000-27b8243c8044a7b773d6
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-014i-4901000000-5aa5b2f932314490dffa
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0ul0-2012930000-aa9829e28f63e60e9b73
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0670-9532100000-3635db42ba41b92e74cb
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0fl0-7275900000-452e44c63684fcad07f6
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-197.17313
predicted
DeepCCS 1.0 (2019)
[M+H]+199.56868
predicted
DeepCCS 1.0 (2019)
[M+Na]+205.4812
predicted
DeepCCS 1.0 (2019)

Drug created at May 11, 2015 22:10 / Updated at April 15, 2024 04:05